An affiliate of South Korean biopharmaceutical firm Celltrion said Wednesday that the market share of its biosimilar Herzuma reached 10 percent in Europe during the fourth quarter of last year.
Celltrion Healthcare, which handles Celltrion’s overseas business, said Herzuma’s market share reached the mark less than six months after the company launched its breast cancer biosimilar drug in seven European countries. The tally was conducted by market researcher IQVIA
Herzuma was approved for the treatment of people diagnosed with early-stage breast cancer, metastatic breast cancer and metastatic gastric cancer. It is based on the blockbuster pill Herceptin, also known as Trastuzumab, developed by Swiss pharmaceutical giant Roche Holding.
Annual global sales of the megahit Herceptin stand at 8.15 trillion won ($7.1 billion), and the European market is estimated to be worth 2.2 trillion won, Celltrion Healthcare said.
“Herzuma has shown fast growth by recording the top market share among Trastuzumab biosimilars in Europe,” a company official, who asked not to be named, said.
By Ram Garikipati and newswires (firstname.lastname@example.org)